Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic.
BioNTech（biontech）股份有限公司（纳斯达克代码：BNTX）和Moderna（moderna）股份有限公司（纳斯达克代码：MRNA）在个人化癌症疫苗方面取得了进展，利用了COVID-19大流行期间的mRNA技术。
Also Read: FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot.
此外，FDA批准了辉瑞和Moderna的更新版COVID疫苗，但却没有包括诺瓦瓦克斯医药的产品。
These companies, whose stocks plummeted by about 80% since their 2021 pandemic peaks, are now focusing on cancer treatments to revive their fortunes.
这些公司的股票自2021年大流行的高峰以来暴跌约80%，现在它们正在聚焦于癌症治疗以重振其命运。
The personalized approach, though promising, faces skepticism due to the high cost and difficulty of scaling production.
尽管个人化方法前景看好，但由于高昂的成本和生产规模的困难，它面临着怀疑。
Miranda Payne, a melanoma specialist leading a Moderna trial at Oxford's Churchill Hospital, expressed excitement about the potential but noted the challenges in making these vaccines widely available.
牛津大学丘吉尔医院的黑素瘤专家Miranda Payne在领导一项Moderna试验时表达了对潜力的兴奋，但同时指出了普遍供应这些疫苗的挑战。
The Financial Times notes the high cost of sequencing each patient's tumor and producing bespoke vaccines raises concerns about the feasibility of widespread application.
《金融时报》注意到每个患者的肿瘤测序和定制疫苗的高成本引发了对广泛应用可行性的担忧。
Moderna's melanoma vaccine, developed in partnership with Merck & Co Inc (NYSE:MRK), is in advanced trials, while BioNTech's product, co-developed with Roche Holdings AG's (OTC:RHHBY) subsidiary Genentech, is being tested in an NHS trial.
Moderna与Merck＆Co Inc（纽约证券交易所：MRK）合作开发的黑色素瘤疫苗正在进行高级试验，而BioNTech与Roche Holdings AG（场外交易：RHHBY）旗下的Genentech合作开发的产品正在进行NHS试验中。
Also Read: Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients.
此外还有：Moderna和Merck公布了高风险黑素瘤患者个体化癌症治疗三年数据。
Despite the optimism, experts caution that while the individual approach is exciting, the high costs and challenges of production make it uncertain whether these personalized vaccines will be scalable or affordable.
尽管乐观，但专家们警告说，尽管个体化方法令人兴奋，但高昂的成本和生产挑战使得这些个性化疫苗能否具有可扩展性或可负担性成为不确定因素。
Uğur Şahin, CEO of BioNTech, emphasized the importance of innovation in personalizing mRNA vaccines, predicting that these treatments could be as impactful as existing immunotherapies by 2030.
BioNTech的首席执行官Uğur Şahin强调了个性化mRNA疫苗创新的重要性，并预测到2030年，这些治疗可能会像现有的免疫治疗方法一样具有影响力。
Moderna is likely to bring its cancer vaccine to market first, focusing on lung and skin cancers. The company is also investing in new manufacturing facilities to improve production efficiency. BioNTech is taking a dual approach, developing personalized and off-the-shelf vaccines to address different cancer types.
Moderna很可能率先将其癌症疫苗引入市场，重点放在肺癌和皮肤癌上。该公司还在投资新的制造设施，以提高生产效率。BioNTech采取双重方法，开发个体化和现成的疫苗以应对不同的癌症类型。
As BioNTech and Moderna push forward, the cancer treatment landscape could be transformed, but the journey is fraught with obstacles.
随着BioNTech和Moderna的推进，癌症治疗前景可能会发生变化，但这个过程充满了许多困难。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside.
- Bullish Analyst认为，NewAmsterdam Pharma的降低胆固醇药物销量将巨大增长。